Zacks Research Has Pessimistic Outlook of Pfizer Q2 Earnings

Pfizer Inc. (NYSE:PFE - Free Report) - Research analysts at Zacks Research cut their Q2 2026 earnings estimates for shares of Pfizer in a note issued to investors on Thursday, March 20th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will earn $0.57 per share for the quarter, down from their prior estimate of $0.58. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Zacks Research also issued estimates for Pfizer's FY2027 earnings at $2.96 EPS.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the firm posted $0.10 earnings per share. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year.

Other analysts have also issued reports about the stock. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Bank of America reissued a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Remove Ads

Pfizer Price Performance

Pfizer stock traded down $0.16 during midday trading on Monday, hitting $25.05. The company's stock had a trading volume of 50,635,576 shares, compared to its average volume of 36,807,534. Pfizer has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock's 50-day moving average price is $26.12 and its 200-day moving average price is $26.98. The company has a market capitalization of $142.08 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Nordea Investment Management AB increased its position in Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after buying an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI grew its position in Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after purchasing an additional 159,984 shares during the last quarter. NFJ Investment Group LLC increased its holdings in shares of Pfizer by 12.8% during the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock worth $11,129,000 after purchasing an additional 43,719 shares during the period. Daiwa Securities Group Inc. raised its position in shares of Pfizer by 25.9% during the third quarter. Daiwa Securities Group Inc. now owns 804,522 shares of the biopharmaceutical company's stock valued at $23,283,000 after buying an additional 165,611 shares during the last quarter. Finally, Copley Financial Group Inc. acquired a new stake in Pfizer during the third quarter worth about $577,000. Institutional investors and hedge funds own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.